Valemetostat tosylate

Description:
Valemetostat is a histone methyltransferase inhibitor that inhibits the catalytic activity of lysine methyltransferases, which are enzymes that add methyl groups to histones. Valemetostat has been shown to be an antineoplastic agent in stem-cell cultures and animal models, although its mechanism of action is not yet elucidated. Valemetostat is currently being studied as a treatment for cancer in humans. Valemetostat inhibits the transcriptional activation by binding to the histones H3 and H4, preventing them from binding to DNA. This prevents transcription and synthesis of proteins that regulate cellular function, leading to cell death.